• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Vitamin D supplementation is not preventative for statin-associated muscle symptoms or statin discontinuation

byGursharan SohiandYuchen Dai
November 27, 2022
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A randomized controlled trial found that pretreatment with supplemental vitamin D did not reduce the risk of statin-associated muscle symptoms in adult patients.

2. Vitamin D supplementation also did not reduce the risk of statin discontinuation.

Level of Evidence Rating: 1 (Excellent)

Study Rundown: Statins are amongst the most common medications prescribed in North America for dyslipidemia and heart protection. Adverse effects include statin-associated muscle symptoms (SAMS), which can be bothersome and frequently lead to medication discontinuation. Recently, low-grade evidence has emerged for vitamin D supplementation as a potentially effective means of reducing the incidence of SAMS in patients using statins. This study represents a secondary analysis of alternate outcomes (rate of SAMS and statin discontinuation) from a randomized controlled trial seeking to assess the effect of vitamin D on cancer risk in statin users.

In total, 25,871 participants were randomized. At baseline, 8890 (34%) of patients were taking a statin; of those who were not on statin therapy at baseline, 2,835 reported taking a statin during the follow-up period. 31% of patients in both the vitamin D and placebo groups reported muscle symptoms while taking a statin medication. The rate of statin discontinuation was also the same in both groups at 13%. Baseline serum measurements of vitamin D levels were also not different between the two groups.

This secondary analysis of the VITAL trial demonstrated that vitamin D supplementation does not affect the risk of experiencing SAMS in adult patients taking statin medications. Strengths of this study included the randomized trial design, which does well to control for confounding and the large study size. Drawbacks of this study include the inability to assess statin compliance as well as chronology (i.e., the timing of SAMS compared to initiation of statin therapy). Future studies should work to elucidate other agents which may be helpful in preventing SAMS in statin users.

RELATED REPORTS

Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule

Novo Nordisk’s Rybelsus demonstrates reduction in cardiovascular events for patients with Type 2 diabetes and cardiovascular disease

High cardiovascular disease mortality among Native Hawaiian and Pacific Islander adults

Click here to read this study in JAMA Cardiology

Relevant reading: Statin-associated muscle disease: advances in diagnosis and management

In-Depth [randomized controlled trial]: Data from this study was derived from the VITAL (vitamin D and omega-3) study, a large randomized controlled trial seeking to assess the impact of vitamin D supplementation on cancer risk in statin-users. Eligible patients were men over the age of 50 and women over the age of 55 who had no cardiovascular disease or cancer history. Participants were randomized to receive vitamin D supplements (2000 IU per day), omega-3 supplements or a placebo and completed a survey about the medications they were taking at baseline and over a series of follow-up questionnaires. Patient enrolment took place between November 2011 and March 2014; the mean follow-up time was 4.8 years.

Overall, 31% of patients in both the vitamin D and the placebo group reported SAMS. Therefore, the adjusted odds ratio for SAMS in the vitamin D group versus placebo was 0.97 (95% confidence interval 0.80-1.18). 13% of patients in both groups discontinued the statin medication; the adjusted odds ratio for discontinuation was 1.04 (0.80-1.35).

Amongst patients who underwent serum vitamin D measurements over the study course, baseline levels were the same in both groups, with a mean level of 30.4 ng/mL and a median level of 30.0 ng/mL. The frequency of SAMS amongst patients with serum vitamin D measurements was also not different between groups: 28% of the vitamin D supplementation patients vs 31% of the placebo patients experienced SAMS. The odds ratio for SAMS in vitamin D users versus placebo participants who had serum vitamin D measurements was 0.86 (95% CI, 0.69-1.09).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular diseaseSAMSstatin associated muscle symptomsstatin discontinuationvitamin D supplementation
Previous Post

Adding autologous tumor lysate-loaded dendritic cell vaccination to standard of care associated with clinical improvement in overall survival for patients with newly diagnosed and recurrent glioblastoma

Next Post

2 Minute Medicine Rewind November 28, 2022

RelatedReports

Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Pharma

Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule

March 25, 2025
Type 2 diabetes associated with reduction in disability-free life years
Pharma

Novo Nordisk’s Rybelsus demonstrates reduction in cardiovascular events for patients with Type 2 diabetes and cardiovascular disease

December 2, 2024
Successful regional implementation of pediatric chest pain algorithm
Cardiology

High cardiovascular disease mortality among Native Hawaiian and Pacific Islander adults

October 16, 2024
#VisualAbstract Edoxaban Monotherapy has Lower Risks for Atrial Fibrillation and Stable Coronary Artery Disease than Dual Antithrombotics
StudyGraphics

#VisualAbstract Edoxaban Monotherapy has Lower Risks for Atrial Fibrillation and Stable Coronary Artery Disease than Dual Antithrombotics

September 10, 2024
Next Post
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

2 Minute Medicine Rewind November 28, 2022

Reduced gestational weight gain with lifestyle intervention

Regular physical activity may improve vaccine effectiveness against COVID-19 outcomes

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

REDUCE-IT Trial: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia [Classics Series]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Digital health apps may have limited role in reduction of migraine symptoms
  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.